The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of PIK3CA mutation in esophageal cancer: Molecular profiling by next-generation sequencing using formalin-fixed, paraffin-embedded tissues.
 
Tomoya Yokota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Merck Serono; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Masakuni Serizawa
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Kimihide Kusafuka
No Relationships to Disclose
 
Keita Mori
Honoraria - Chugai Pharma
Consulting or Advisory Role - Shizuoka Industrial Foundation Pharma Valley Center; Shizuoka Industrial Foundation Pharma Valley Center
 
Toshiro Sugiyama
Consulting or Advisory Role - Eisai
Research Funding - Pfizer
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Yasuhiro Koh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Ono Pharmaceutical; Thermo Fisher Scientific; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis